The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens
Abstract
We find that tamoxifen is a potent activator of estrogen receptor (ER)- mediated induction of promoters regulated by AP-1 sites including the human collagenase gene promoter and constructs in which an AP-1 site is fused to the herpes thymidine kinase promoter. This contrasts with the inability of tamoxifen to activate otherwise identical promoters bearing classical estrogen response elements. Tamoxifen agonism at AP-1 sites is cell type specific, occurring in cell lines of uterine, but not of breast, origin. It thus parallels tamoxifen agonism in vivo. AP-1 proteins such as Jun or Jun/Fos are needed for tamoxifen stimulation, and tamoxifen increases the transcriptional efficiency of these proteins even when they are provided at optimal amounts. The DNA binding domain (DBD) of ER is required for tamoxifen activation at AP-1 sites. In contrast, estrogen activation is partially independent of this domain. This suggests the existence of two pathways of ER action at AP-1: an alpha (DBD-dependent) pathway activated by tamoxifen, and a beta (DBD-independent) pathway activated by estrogen. Fusing VP16 transcriptional activation functions to ER potentiates the beta, but not the alpha, pathway. We discuss models for the two pathways and the possibility that the AP-1 pathway is a major route by which ER affects target tissue growth and differentiation in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Yang-Yen, H.-F., Chambard, J.-C., Sun, Y.-L., Smeal, T., Schmidt, T. J., Drouin, J., & Karin, M. (1990) · Cell · doi:10.1016/0092-8674(90)90396-v · Cited by 1,553
The c-fos protein interacts with c-JunAP-1 to stimulate transcription of AP-1 responsive genes
Chiu, R., Boyle, W. J., Meek, J., Smeal, T., Hunter, T., & Karin, M. (1988) · Cell · doi:10.1016/0092-8674(88)90076-1 · Cited by 1,335
Functional domains of the human estrogen receptor
Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.-R., & Chambon, P. (1987) · Cell · doi:10.1016/0092-8674(87)90581-2 · Cited by 1,316
(1991) · PubMed · Cited by 1,101
Xanthoudakis, S., & Curran, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05097.x · Cited by 708
Angel, P., Baumann, I., Stein, B., Delius, H., Rahmsdorf, H. J., & Herrlich, P. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.6.2256 · Cited by 694
Turner, R., & Tjian, R. (1989) · Science · doi:10.1126/science.2494701 · Cited by 648
Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex
Gaub, M.-P., Bellard, M., Scheuer, I., Chambon, P., & Sassone-Corsi, P. (1990) · Cell · doi:10.1016/0092-8674(90)90422-b · Cited by 468
Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.
Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4037 · Cited by 465
Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., & Parker, M. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6883 · Cited by 396
IP-1: A dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylation
Auwerx, J., & Sassone-Corsi, P. (1991) · Cell · doi:10.1016/0092-8674(91)90322-p · Cited by 205
Baichwal, V. R., & Tjian, R. (1990) · Cell · doi:10.1016/0092-8674(90)90147-7 · Cited by 199
Shemshedini, L., Knauthe, R., Sassone-Corsi, P., Pornon, A., & Gronemeyer, H. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04953.x · Cited by 189
The future of new pure antiestrogens in clinical breast cancer
Wakeling, A. E. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00662395 · Cited by 131
Structure and Function of the Estrogen Receptor
PARKER, M. G., ARBUCKLE, N., DAUVOIS, S., DANIELIAN, P., & WHITE, R. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb32276.x · Cited by 129
Anzai, Y., Holinka, C. F., Kuramoto, H., & Gurpide, E. (1989) · PubMed · Cited by 109
Tzukerman, M., Zhang, X.-K., & Pfahl, M. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1983 · Cited by 95
Positive and Negative Modulation of Jun Action by Thyroid Hormone Receptor at a Unique AP1 Site
Lopez, G. N., Schaufele, F., Webb, P., Holloway, J. M., Baxter, J. D., & Kushner, P. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.5.3042 · Cited by 83
Self-citationv-Src and EJ Ras alleviate repression of c-Jun by a cell-specific inhibitor
Baichwal, V. R., Park, A., & Tjian, R. (1991) · Nature · doi:10.1038/352165a0 · Cited by 78
The strategic use of antiestrogens to control the development and growth of breast cancer.
Jordan, V. C. (1992) · PubMed · Cited by 77
Jamil, A., Croxtall, J. D., & WHITE, J. O. (1991) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0060215 · Cited by 69
Eukaryotic regulatory elements lurking in plasmid DNA: the activator protein-1 site in pUC.
Kushner, P. J., Baxter, J. D., Duncan, K. G., Lopez, G. N., Schaufele, F., Uht, R. M., Webb, P. M., & West, B. L. (1994) · Molecular Endocrinology · doi:10.1210/mend.8.4.8052261 · Cited by 62
Self-citationActivation of Jun/AP-1 by protein kinase A.
de Groot, R. P., & Sassone‐Corsi, P. (1992) · PubMed · Cited by 56
Baichwal, V. R., Park, A., & Tjian, R. (1992) · Genes & Development · doi:10.1101/gad.6.8.1493 · Cited by 50
Tamoxifen's effects on the zebra finch song system are estrogenic, not antiestrogenic
Mathews, G. A., & Arnold, A. P. (1991) · Journal of Neurobiology · doi:10.1002/neu.480220907 · Cited by 47
The Stimulation of Uterine Complement Component C3 Gene Expression by Antiestrogens
Sundstrom, S. A., Komm, B. S., Xu, Q. S., Boundy, V. A., & Lyttle, C. R. (1990) · Endocrinology · doi:10.1210/endo-126-3-1449 · Cited by 44
Effect of antioestrogens on the DNA binding activity of oestrogen receptorsin vitro
Arbuckle, N. D., Dauvois, S., & Parker, M. G. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.15.3839 · Cited by 43
Current Approaches to Breast Cancer Prevention
Henderson, M. (1993) · Science · doi:10.1126/science.8430311 · Cited by 24
Spatz, M., Waisman, A., & Kaye, A. M. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90409-c · Cited by 17
Cited by
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Nilsson, S., Mäkelä, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., & Gustafsson, J.-Å. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.4.1535 · Cited by 1,996
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Björnström, L., & Sjöberg, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0486 · Cited by 1,362
Kavlock, R. J., Daston, G. P., DeRosa, C., Fenner-Crisp, P., Gray, L. E., Kaattari, S., Lucier, G., Luster, M., Mac, M. J., Maczka, C., et al. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104s4715 · Cited by 1,149
Metadata
- Authors
- Webb, P.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1995-04-01
- Volume
- 9
- Issue
- 4
- Pages
- 443-456
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W1964957120
- Cited by
- 693
- References
- 30
- FWCI
- 23.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.